Kymera Therapeutics Reports Positive Results from Phase 1 Trial of KT-579 for Immunological Diseases

Kymera Therapeutics announced positive results from its Phase 1 healthy volunteer trial for KT-579, an investigational oral degrader targeting IRF5 for immunological diseases. The trial demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers, and a favorable safety profile. The company plans to initiate a Phase 1b trial in lupus patients by early 2027.